Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30917332 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTGAAMEN1KMT2A | |
| SCHEMBL561284 | 0.91 | HTT (0.64) | SMN1; SMN2HTTGAAMEN1KMT2A | |
| Methyl 3,5-Dinitrobenzoate SCHEMBL418416 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2HTTGAAMEN1KMT2A | |
| SCHEMBL8762477 | 0.86 | HTT (0.59) | SMN1; SMN2HTTGAAMEN1KMT2A | |
| SCHEMBL728757 | 0.86 | ALDH1A1 (0.66) | SMN1; SMN2HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL38446 | 0.85 | HTT (0.58) | SMN1; SMN2HTTGAAMEN1KMT2A | |
| SCHEMBL4731202 | 0.85 | HTT (0.58) | SMN1; SMN2HTTGAAMEN1KMT2A | |
| SCHEMBL16960801 | 0.85 | HTT (0.58) | SMN1; SMN2HTTGAAMEN1KMT2A | |
| SCHEMBL583563 | 0.85 | HTT (0.58) | SMN1; SMN2HTTGAAMEN1KMT2A | |
| SCHEMBL4531505 | 0.84 | CA1 (0.58) | SMN1; SMN2HTTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118108621-A | Diamine compound, heat-resistant resin, resin composition, cured film, and electronic component | 东友精细化工有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-110028419-B | Preparation method of iopromide | 台州学院 | 2022-01-21 | — | — | CN | disclosed |
| CN-111410615-A | Preparation method and application of iopromide intermediate | 正大天晴药业集团股份有限公司 | 2020-07-14 | — | — | CN | disclosed |
| US-8470860-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2013-06-25 | — | — | US | disclosed |
| US-8470860-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2013-06-25 | — | — | US | disclosed |
| US-8470860-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2013-06-25 | — | — | US | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2468752-A1 | Thiazolopyridine derivatives as sirtuin-modulators | Sirtris Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8178536-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178536-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-0008154-A1 | Ureylene phenylene anionic naphthalene-sulfonic acids, their use as complement system inhibitors in a body fluid and process for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-02-20 | — | — | EP | disclosed |
| US-4185033-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1980-01-22 | — | — | US | disclosed |
| US-4185032-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1980-01-22 | — | — | US | disclosed |
| US-4177209-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1979-12-04 | — | — | US | disclosed |
| US-4155931-A | COMPLEMENT INHIBITORS FOR MAMMALS | AMERICAN CYANAMID COMPANY (US) | 1979-05-22 | — | — | US | disclosed |
| US-4129590-A | INHIBITORS OF THE COMPLEMENT SYSTEM | AMERICAN CYANAMID COMPANY (US) | 1978-12-12 | — | — | US | disclosed |
| US-4120891-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1978-10-17 | — | — | US | disclosed |
| US-4052444-A | DIAZO COUPLERS FOR MONOAZO DYES | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-10-04 | — | — | US | disclosed |
| US-4032567-A | TRIIODOISOPHTHALIC ACID MONOAMINO ACID AMIDES, PROCESS FOR THE PREPARATION THEREOF, AND USE THEREOF AS X-RAY CONTRAST MEDIA | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-06-28 | — | — | US | disclosed |
| US-3953501-A | X-RAY CONTRAST AGENTS | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | SMN1; SMN2 1572/4885HTT 234/4885GAA 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.